CA2223402A1 - Procedes d'inhibition de la phagocytose - Google Patents

Procedes d'inhibition de la phagocytose

Info

Publication number
CA2223402A1
CA2223402A1 CA002223402A CA2223402A CA2223402A1 CA 2223402 A1 CA2223402 A1 CA 2223402A1 CA 002223402 A CA002223402 A CA 002223402A CA 2223402 A CA2223402 A CA 2223402A CA 2223402 A1 CA2223402 A1 CA 2223402A1
Authority
CA
Canada
Prior art keywords
gamma
receptor
sequence
cell
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002223402A
Other languages
English (en)
Other versions
CA2223402C (fr
Inventor
Alan D. Schreiber
Jong-Gu Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2223402A1 publication Critical patent/CA2223402A1/fr
Application granted granted Critical
Publication of CA2223402C publication Critical patent/CA2223402C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte, en général, à des procédés de traitement de maladies dues à des interactions entre des complexes immuns et des récepteurs Fc. La présente invention se rapporte notamment à des procédés permettant de moduler l'élimination de la circulation de cellules recouvertes d'anticorps, qui consistent à inhiber la phagocytose, et à des procédés de modulation de l'interaction des complexes immuns avec les récepteurs Fc des tissus. L'invention se rapporte en outre à des procédés de modulation de l'activation des processus immunologiques induits par l'activation des récepteurs Fc due à l'interaction anticorps-antigènes/récepteurs.
CA2223402A 1995-06-07 1996-06-07 Procedes d'inhibition de la phagocytose Expired - Fee Related CA2223402C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48353095A 1995-06-07 1995-06-07
US08/483,530 1995-06-07
PCT/US1996/010494 WO1996040199A1 (fr) 1995-06-07 1996-06-07 Procedes d'inhibition de la phagocytose

Publications (2)

Publication Number Publication Date
CA2223402A1 true CA2223402A1 (fr) 1996-12-19
CA2223402C CA2223402C (fr) 2012-07-31

Family

ID=23920431

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2223402A Expired - Fee Related CA2223402C (fr) 1995-06-07 1996-06-07 Procedes d'inhibition de la phagocytose

Country Status (6)

Country Link
EP (1) EP0831875A4 (fr)
JP (1) JPH11507824A (fr)
AU (1) AU723595B2 (fr)
CA (1) CA2223402C (fr)
IL (1) IL122338A0 (fr)
WO (1) WO1996040199A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
EP1006183A1 (fr) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Récepteurs Fc recombinantes et solubles
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
JP2004536800A (ja) * 2001-05-09 2004-12-09 アルカベロ アクチェセルスカプ Ｔｈ１／ｔｈ２比を変調することによりｔｈ１及びｔｈ２細胞関連疾患を予防又は治療するための医薬組成物
WO2005049838A2 (fr) 2003-11-14 2005-06-02 Yale University Interference par acide nucleique ciblee sur syk
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111105A (en) * 1993-09-30 2009-05-04 Univ Pennsylvania Use of a molecule capable of inhibiting the expression of syk kinase to prepare a pharmaceutical composition for inhibiting phagocytosis
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
PL314522A1 (en) * 1993-11-23 1996-09-16 Ciba Corning Diagnostics Corp Application of antisense oligomers in a contamination controlling process during nucleic acids amplification reactions

Also Published As

Publication number Publication date
EP0831875A4 (fr) 2002-07-31
CA2223402C (fr) 2012-07-31
JPH11507824A (ja) 1999-07-13
AU723595B2 (en) 2000-08-31
AU6386996A (en) 1996-12-30
IL122338A0 (en) 1998-04-05
EP0831875A1 (fr) 1998-04-01
WO1996040199A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
Li et al. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation
CA2570324C (fr) Proteines hybrides rage et leurs procedes d'utilisation
EP0769552A1 (fr) Compose d'acide nucleique antisens
NZ552842A (en) Rage fusion proteins and methods of use
Kluger 6. Vascular endothelial cell adhesion and signaling during leukocyte recruitment
Adamo et al. New Ca2+ pump isoforms generated by alternative splicing of rPMCA2 mRNA
AU2007215503A1 (en) Rage fusion proteins and methods of use
D'Agostaro et al. Molecular Cloning and Expression of cDNA Encoding the Rat UDP-N-Acetylglucosamine: α-6-D-Mannoside β-1, 2-N-Acetylglucosaminyltransferase II (∗)
EP1670903B1 (fr) Traitement de maladies neurodegeneratives
US11976279B2 (en) Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
CA2172392A1 (fr) Methode d'inhibition de la phagocytose
JP2024518476A (ja) ｍＲＮＡスプライシングを調節するための組成物及び方法
US20080213813A1 (en) Histone deacetylase inhibitor and use thereof
EP1778837B1 (fr) Utilisation d'inhibiteurs de scd4 pour le traitement de maladies dégénératives
EP3735981B1 (fr) Protéine 2 contenant le domaine du sperme motile et inflammation
CA2223402C (fr) Procedes d'inhibition de la phagocytose
Challah et al. Cardiac angiotensin converting enzyme overproduction indicates interstitial activation in renovascular hypertension
Talento et al. Transfection of mouse cytotoxic T lymphocyte with an antisense granzyme A vector reduces lytic activity
WO1996040199A9 (fr) Procedes d'inhibition de la phagocytose
Brodsky Characterization of the (Na+ (+) K+)-ATPase from 3T3-F442A fibroblasts and adipocytes. Isozymes and insulin sensitivity.
EP3253777B9 (fr) Peptides dérivés de glycoprotéines du virus rabique (rvg)
Hasegawa et al. Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects
JP4574992B2 (ja) プラスミノーゲンアクチベーター阻害剤−１を阻害するためのｄｎａ酵素
Fujiwara et al. Antisense oligodeoxynucleotides against thrombomodulin suppress the cell growth of lung adenocarcinoma cell line A549
EP1716176B1 (fr) Variants d'epissage cd38 et leurs utilisations

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140609